Day 0 bone marrow pathology of allogeneic hematopoietic stem cell transplantation is a novel prognostic factor in myeloid malignancies

Takahiko Sato1, Naomi Kawashima1, Masafumi Ito2, Yoshiko Atsuta3, Yusuke Kagaya1, Aika Seto1, Takanobu Morishita1, Nobuaki Fukushima1, Yukiyasu Ozawa1, Koichi Miyamura1

1Department of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 2Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan, 3Japanese Data Center for Hematopoietic Cell Transplantation, Nagoya, Japan

Abstract

Residual disease (RD) is one of the risk factors for relapse after hematopoietic stem cell transplantation (HSCT) in hematological malignancies. Although recent advances in the technology for detecting minimal/measurable RD, such as multiparameter flow cytometry and quantitative PCR, enable risk stratifications of disease relapse, these examinations still have limitations in routine clinical practice. In this study, we assessed RD in bone marrow (BM) specimens on day 0 of allogeneic HSCT by immunostaining of case-specific leukemic blast markers and analyzed the relationship between day 0 BM status and HSCT outcomes. We analyzed 82 adult HSCT recipients with myeloid malignancies. BM histology of day 0 revealed almost empty marrow with a small number of residual BM cells. However, residual blasts could be detected by immunostaining even for only a few cells. When patients were divided into two groups according to the existence of RD on day 0, those with positive RD showed significantly lower overall survival rate (27% vs. 73%, \( P < 0.001 \)) and higher cumulative incidence of relapse (46% vs. 9%, \( P = 0.006 \)) at one year compared to those with negative RD. Furthermore, even if they were not in remission at the point of the pre-conditioning evaluation, the patients who achieved negative RD on day 0 showed comparable prognosis with those who maintained remission before conditioning. This study shows the efficacy of day 0 BM pathology of allogeneic HSCT as a prognostic factor that can contribute to clinical decisions on post-transplant strategies.

Key words: bone marrow pathology, allogeneic hematopoietic stem cell transplantation, minimal residual disease, myeloid malignancies, relapse

Submitted June 6, 2020; Accepted August 9, 2020; Published online October 16, 2020; Issued online November 25, 2020
Correspondence: Naomi Kawashima, Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Japan, E-mail: nkawashima@med.nagoya-u.ac.jp

Introduction

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curable therapy for hematological malignancies. However, relapse remains an obstacle for patients' survival1,2. Minimal/measurable residual disease is considered as one of the risk factors for relapse after allo-HSCT3,4. It is widely known that patients without hematological remission have poor outcomes after allo-HSCT5,6. In a previous report of refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), low leukemia burden, less than 5% blasts in bone marrow (BM) with the absence of peripheral blood blasts at the time of transplant, showed better overall survival (OS) than higher leukemia burden with more BM blast counts and circulating blasts7. Recent advances in the technology for detecting minimal residual disease including multiparameter flow cytometry, quantitative PCR and next-generation sequencing also enabled identification of poor responders to chemotherapy and provided risk stratifications8-10. However, they are based on the evaluation before conditioning treatment in the setting of allo-HSCT.

In patients with residual diseases (RD), BM status at
the point of stem cell infusion, namely after conditioning treatment, potentially differs from that of pre-conditioning assessment, depending upon the response to conditioning chemotherapy and irradiation or proliferative potency of the residual blasts. Therefore, the evaluation of disease status on day 0 marrow could predict post-transplant outcomes and help planning upfront post-transplant strategies for residual diseases. In the present study, we histopathologically evaluated the BM on day 0 of allo-HSCT and its impact on outcomes after allo-HSCT.

Patients and Methods

Patients

We retrospectively analyzed a total of 82 consecutive adult patients who received a first allo-HSCT for AML or MDS with excess blasts (MDS-EB) between 2010 and 2014 in Japanese Red Cross Nagoya First Hospital. Patients with extramedullary diseases were excluded from the study. This study was approved by the ethical committee of our institutional review board and all patients provided informed consent in accordance with the Declaration of Helsinki.

Pathological examinations

BM examinations were performed routinely before conditioning treatment and on day 0 of stem cell infusion. BM clot sections before conditioning treatment and the day of stem cell infusion were examined by histopathology and immunostaining. All specimens were fixed in 10% formalin solution and embedded in paraffin. All slides were stained with hematoxylin and eosin as well as with the naphthol AS-D chloroacetate esterase plus Giemsa double staining (ASD-G) method. Immunostaining was conducted using a Leica Bond-IIITM according to instruction manuals (Leica Biosystems, Newcastle, UK). CD7, CD34, CD56, CD117 (c-kit), TdT, and p53 antibodies (Leica Biosystems, Newcastle, UK) were used in this study. Antibodies were selected according to the specific blast tumor phenotypes in individual cases.

Definitions

Detection of a single residual blast by immunostaining in a whole BM clot section on day 0 was defined as positive RD (Day 0-RD+), whereas patients without a residual blast were defined as negative RD (Day 0-RD−). In patients with MDS-EB, dysplasia in residual BM cells was not considered but only the existence of residual blasts by immunostaining was defined as RD in this study. Hematological remission was defined as less than 5% of blasts in BM smear samples evaluated by each physician.

Neutrophil engraftment post allo-HSCT was defined as the achievement of an absolute neutrophil count ≥500/μl for three consecutive days. Myeloblastic conditioning (MAC) was defined as a conditioning regimen with at least 8 Gy of total body irradiation or busulfan administration over 16 mg/kg. All other regimens were categorized as reduced-intensity conditioning (RIC).

Statistical analyses

Overall survival (OS) was measured from the date of stem cell infusion to the date of death from any cause or the last follow-up (censoring). Survival curves were plotted by the Kaplan-Meier method, and univariate analyses were performed with the log-rank test. Competing risk analyses were used to estimate the cumulative incidence of relapse, and univariate analyses were performed with Gray’s test. All variables with \( P < 0.1 \) from univariate analyses were included in the multivariate analyses, which were performed with either the Cox proportional hazard regression model or the Fine-Gray competing risks regression model. All statistical tests were two-sided, and statistical significance was defined as \( P < 0.05 \). All statistical analyses were performed with EZR 1.30 (Saitama Medical Center, Jichi Medical University, Saitama, Japan)\(^\text{11}\).

Results

Pathology of day 0 bone marrow

BM clot sections of pre-conditioning and day 0 stained with ASD-Giemsa and anti-CD34 antibody are shown in Figure 1. BM histology of Day 0-RD− revealed almost empty marrow with a small number of residual mature granulocytes, erythroblasts, lymphocytes and macrophages compared with normoplastic BM before conditioning treatment (Figure 1A). Although BM blasts could be identified by ASD-G staining in few cases, residual blasts were able to be detected even for only a few cells by using immunostaining of case-specific markers in BM of Day 0-RD+ group (Figure 1B).

Patient characteristics

Within the 82 patients, 71 (86.6%) were included in Day 0-RD− group and 11 (13.4%) were in Day 0-RD+ group, whose characteristics are summarized in Table 1. All of the patients were not in hematological complete remission (nCR) before conditioning treatment in Day 0-RD− group, whereas 27 of 71 patients (38.0%) in Day 0-RD− group were nCR before conditioning but blast cells were not detected on day 0 (\( P < 0.001 \), Table 1). Among the other 44 patients in Day 0-RD− group who were in hematological CR before conditioning, molecular RD was also assessed in BM before conditioning of 19 patients by measuring the expression levels of chimeric transcripts of \( CBFB-MYH11 \) (n = 3) and \( DEK-NUP214 \).
and Wilms tumor 1 (WT1) mRNA (n = 14). Molecular RD was detectable before conditioning in 13 patients with positive WT1 mRNA (median 900, range 230-32,000 copies/μg RNA).

The median percentage of BM blasts before conditioning was significantly higher in Day 0-RD+ group than Day 0-RD− group (71% vs. 3%, P < 0.001), which had no significant correlation with the blast percentage of day 0 marrow (Spearman rank order correlation coefficient, rs = 0.47). When limited to patients with nCR at pre-conditioning, the median percentage of BM blasts was higher in the Day 0-RD− group than the Day 0-RD+ group in AML (83% vs. 19%, P = 0.01); however, it was similar between the two groups in MDS-EB (17% vs. 11%, P = 0.28).

Positive residual disease in Day 0 BM was an independent risk factor for survival and relapse

The intensity of conditioning regimen had no significant impact on day 0 marrow status (P = 0.53). Eleven of 27 patients (41%) including 6 of 13 MDS patients (46%) in nCR before conditioning received MAC and achieved Day 0-RD− status, whereas 5 of 11 (45%) in nCR before conditioning received MAC and stayed in Day 0-RD+. Neutrophil engraftment was achieved in 78 patients (95%) at a median of 16 days (range 10-42 days) and no significant difference was observed based upon the day 0 BM status (P = 0.38).

Median follow-up period of survivors was 917 days (range 330-2,092 days) after allo-HSCT. OS rate at 1 year was 27% (95% confidence interval [CI], 7-54%) in patients in Day 0-RD+ group, which was significantly lower than those in Day 0-RD− group (73% [95%CI 61-82%], P < 0.001, Figure 2A). In univariate analyses,
recipient age at transplantation of older than 45 years old, RIC, and Day 0-RD + were extracted as risk factors for OS. By multivariate analysis, Day 0-RD + was identified as an independent risk factor for OS (Table 2). Furthermore, when limited to patients with nCR marrow before conditioning, patients without residual blasts in day 0 marrow (Pre-conditioning nCR/Day 0-RD - group) provided significantly better OS compared with Day 0-RD + group (70% [95% CI, 49-84] and 27% [95% CI, 6.5-54]) at 1 year after allo-HSCT, respectively, \( P < 0.01 \), which was comparable with those who maintained CR before conditioning (Figure 2B). Median time to relapse after allo-HSCT was shorter in the Day 0-RD + group (55 days, range of 0-309 days, \( n = 7 \)) than in the Day 0-RD - group (260 days, range of 92-1,057 days, \( n = 16 \)). The cumulative incidences of relapse at 1 year were 46% (95%CI, 14-73%) in patients in Day 0-RD + group, which was significantly higher than those in Day 0-RD - group (9% [95%CI 3-16%], \( P = 0.006 \), Figure 2C). Of note, there was no significant difference in one-year relapse rate between the patients with CR at the point of pre-conditioning assessment (9.1% [95% CI, 2.8-20]) and those with nCR (7.4% [95% CI, 1.2-21]) when limited to Day 0-RD - cases (\( P = 0.36 \), Figure 2D).

By multivariate analyses, Day 0-RD + status was a significant risk factor for relapse (Table 2). There was no significant difference in non-relapse mortality between Day 0-RD - and Day 0-RD + groups (18% [95% CI, 10-28] and 27% [95% CI, 5.6-56] at 1 year after allo-HSCT, respectively, \( P = 0.49 \)).

Discussion

Relapse after allo-HSCT remains an obstacle to long-
term survival in myeloid malignancies. Therefore, a novel marker to predict relapse is warranted. In this study, we described the efficacy of evaluating day 0 BM of allo-HSCT after completing a conditioning treatment on predicting OS and relapse, providing a new risk stratification that Day 0-RD+ is an independent risk factor for both OS and relapse, whereas Day 0-RD− represents better OS, even if they were not in CR before conditioning treatment as routinely evaluated. Furthermore, patients who were not in CR at the point of pre-conditioning evaluation showed a comparable prognosis to those with CR before conditioning if they achieved negative RD in the day 0 marrow. Of note, residual blast count of pre-conditioning BM was not significantly associated with that of day 0 marrow, suggesting that the status of day 0 BM more specifically predicts the outcomes after allo-HSCT than disease status assessed before conditioning.

In previous reports, the presence of residual AML cells detected by flow cytometry before RIC was associated with significantly increased relapse, shorter disease-free survival, and poorer OS after allo-HSCT, indicating achieving flow cytometric CR is critical to achieve before conditioning treatment. As the cellularity of day 0 marrow is severely hypoplastic and insufficient to perform flow cytometry to analyze their residual diseases (Figure 1A), we used immunohistochemistry of BM clot sections to detect residual blasts in the present study. In this study, minor residual blasts were easily detected even in severely hypoplastic marrow using immunostaining of case-specific blast markers (Figure 1). With this method, residual blasts in BM can be assessed faster and at lower costs than quantitative PCR and next-generation sequencing. Furthermore, this technique can easily be performed in standard hematopoietic stem cell transplantation hospitals. On the other hand, the main limitation of this study is that the detection sensitivity of our method was not validated. Although the existence of histopathological residual diseases in day 0 marrow was shown to

![Figure 2](https://example.com/figure2)

**Figure 2.** Overall survival and cumulative incidence of relapse according to the status of day 0 marrow

(A) Overall survival according to the status of day 0 marrow. (B) Overall survival according to the status of bone marrow before conditioning (pre-conditioning) and on day 0. (C) Cumulative incidence of relapse according to the status of day 0 marrow. (D) Cumulative incidence of relapse according to the status of bone marrow before conditioning (pre-conditioning) and on day 0. Differences between groups were evaluated by the log-rank test (A and B) and Gray’s test (C and D).

NS, not significant.
be a poor prognostic marker in our cohort, BM clot sections are supposed to have histological heterogeneity. Furthermore, the other limitation which may have impacted our findings is that other risk factors of primary diseases such as adverse cytogenetics and genetic alterations were not available for our prognostic analysis. Combined with more sensitive methodologies such as quantitative PCR and next-generation sequencing, more significant and clearer impact of day 0 marrow status on outcomes post allo-HSCT could be described in hematological malignancies.

This is a retrospective analysis in a single institution where day 0 BM was routinely examined. However, BM aspiration on the day of allo-HSCT is not widely performed in clinical practice. The clinical significance of minimal/measurable RD has been reportedly assessed in BM before conditioning treatment. Because all the patients in CR before conditioning treatment showed Day 0-RD− as expected, our results suggest that Day 0 BM evaluation is necessary for only patients in nCR at the point of pre-conditioning assessment to minimize the risk of this invasive procedure.

Regarding the intensity of conditioning, MAC rather than RIC reportedly reduced the incidence of relapse and improved disease-free survival and OS rate after allo-HSCT in patients with residual leukemia. Because all the patients in CR before conditioning treatment showed Day 0-RD− as expected, our results suggest that Day 0 BM evaluation is necessary for only patients in nCR at the point of pre-conditioning assessment to minimize the risk of this invasive procedure.

Therefore, it can be speculated that day 0 BM status reflects sensitivity to conditioning treatment.

In the setting of allo-HSCT, disease relapse can occur when graft-versus-leukemia effects are insufficient to suppress the residual disease. In the Day 0-RD+ group, one patient achieved as long as 684 days of disease-free survival by controlling immunosuppressants and chronic graft-versus-host disease. In summary, we demonstrated the efficacy of immunostaining using blast-specific markers to evaluate residual diseases on day 0 BM of allo-HSCT for the first time. This was a retrospective study including a limited number of patients at a single institution. Therefore, a study in a larger cohort is warranted to confirm the results. Nevertheless, our analyses suggest the detection of Day 0-RD status is a novel prognostic factor that can clinically contribute to constructing post-transplant strategies for improving outcomes in myeloid malignancies.

### Acknowledgements

The authors thank all of the patients who consented to participate in this study.

### Table 2. Multivariate analyses for overall survival and cumulative incidence of relapse

| Variables                          | Adverse factors          | Overall survival | Cumulative incidence of relapse |
|------------------------------------|--------------------------|-----------------|---------------------------------|
|                                    |                          | Univariate      | Multivariate                   | Univariate | Multivariate |
|                                    |                          | p-value         | HR (95%CI)                      | p-value    | HR (95%CI)   | p-value |
| Recipient age >45 years old        | <0.001                   | 3.1 (1.1-8.6)   | 0.03                            | 0.05       | 2.3 (0.90-5.7) | 0.08   |
| Donor-recipient sex female donor to male recipient | 0.55 | — | — | 0.67 | — | — |
| Disease                            | AML                      | 0.83            | —                               | 0.22       | — | — |
| BM before conditioning nCR         | 0.11                     | —               | 0.83                           | — | — |
| Conditioning                       | RIC                      | 0.001           | 1.1 (0.45-2.8)                  | 0.79       | 0.32 | — | — |
| HCT-CI ≥2                         | 0.37                     | —               | 0.20                           | — | — |
| ABO blood type                     | Matched                  | 0.22            | —                               | 0.04       | 3.1 (1.3-7.5) | 0.01 |
| HLA disparity                      | B/B matched              | 0.90            | —                               | 0.74       | — | — |
| Stem cell source CB                | 0.56                     | —               | 0.81                           | — | — |
| GvHD prophylaxis Tac-based         | 0.52                     | —               | 0.13                           | — | — |
| Day 0 marrow RD(+)                 | <0.001                   | 3.7 (1.7-8.1)   | <0.001                         | 0.006      | 4.5 (1.8-11) | 0.001 |

HR, hazard ratio; CI, confidence interval; BM, bone marrow; nCR, not in complete remission; RIC, reduced-intensity conditioning; HCT-CI, hematopoietic cell transplantation specific comorbidity index; HLA, human leukocyte antigen; CB, cord blood; GvHD, graft-versus-host disease; Tac, tacrolimus; RD (+), positive residual disease.

a All variables with P<0.1 from univariate analyses were included in the multivariate analyses performed with the Cox proportional hazard regression model.

b All variables with P<0.1 from univariate analyses were included in the multivariate analyses performed with the Fine-Gray competing risks regression model.
Author Contributions

The study concept and design were developed by TS, NK, KM, and MI. Clinical data collection was performed by TS, NK, and YK. Bone marrow specimens were pathologically assessed by MI. Data analyses and manuscript drafting were done by TS and NK. Discussions involved all authors. Administrative and material support was provided by KM and MI. This study was supervised by MI and KM.

Conflicts of Interest

The authors declare no conflict of interest. Disclosure forms provided by the authors are available here.

References

1. Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone marrow transplantation. 2018; 53: 1379-89.
2. van den Brink MR, Porter DL, Giralt S, Lu SX, Jenq RR, Hanash A, et al. Relapse after allogeneic hematopoietic cell therapy. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2010; 1 Suppl: S138-45.
3. Kroger N, Miyamura K, Bishop MR. Minimal residual disease following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011; 1 Suppl: S94-100.
4. Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, et al. Pre- and post-transplant quantification of measurable (minimal) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016; 30: 1456-64.
5. Song KW, Lipton J. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Bone Marrow Transplant. 2005; 36: 183-91.
6. Chevallier P, Labopin M, Milpied N, Bilger K, Socie G, Yakoub-Agha I, et al. Outcomes of adults with active or progressive hematological malignancies at the time of allo-SCT: a survey from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2014; 49: 361-5.
7. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S, et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant. 2005; 36: 157-62.
8. Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transplant. 2013; 48: 630-41.
9. Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Aloui AM, et al. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 2017; 102: 110-7.
10. Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2020; 55: 843-50.
11. Kanda Y. Investigation of the freely available easy-to-use software ‘EZIR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452-8.
12. Tsirigotis P, Byrne M, Schmid C, Baron F, Ciceri F, Esteve J, et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow transplantation. 2016; 51: 1431-38.
13. Ustun C, Wiseman AC, Defor TE, Yohe S, Linden MA, Oran B, et al. Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML. Bone Marrow Transplant. 2013; 48: 1415-20.
14. Kotrova M, van der Velden VHI, van Dongen JMJ, Formanova R, Sedlacek P, Bruggemann M, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant. 2017; 52: 962-8.
15. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012; 120: 905-13.
16. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129: 424-47.
17. Ustun C, Courville EL, DeFor T, Dolan M, Randall N, Yohe S, et al. Myeloablative, but not Reduced-Intensity, Conditioning Overcomes the Negative Effect of Flow-Cytometric Evidence of Leukemia in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2016; 22: 669-75.
18. Kawashima N, Inamoto Y, Sato T, Nakashima M, Kagaya Y, Watakabe K, et al. Long-term outcomes of allogeneic hematopoietic cell transplantation with intensified myeloablative conditioning for refractory myeloid malignancy. Bone Marrow Transplant. 2016; 51: 869-71.
19. Barrett AJ, Battiwalla M. Relapse after allogeneic stem cell transplantation. Expert Rev Hematol. 2010; 3: 429-41.
20. Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, et al. Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation. Leukemia. 2010; 24: 1462-9.
21. Horn B, Petrovic A, Wahstrom J, Dvorak CC, Kong D, Hwang J, et al. Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric
hematologic malignancies. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2015; 21: 729-37.

22. Chang YJ, Huang XJ. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom? Blood reviews. 2013; 27: 55-62.

https://doi.org/10.31547/bct-2020-007
Copyright © 2020 APBMT. All Rights Reserved.